Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro
© Lieke et al.; licensee BioMed Central Ltd. 2012
Received: 15 May 2012
Accepted: 2 October 2012
Published: 11 October 2012
Cholangiocarcinoma (CC) is a primary liver cancer with increasing incidence worldwide. Despite all efforts made in past years, prognosis remains to be poor. At least in part, this might be explained by a pronounced resistance of CC cells to undergo apoptosis. Thus, new therapeutic strategies are imperatively required. In this study we investigated the effect of Salinomycin, a polyether ionophore antibiotic, on CC cells as an appropriate agent to treat CC. Salinomycin was quite recently identified to induce apoptosis in cancer stem cells and to overcome apoptosis-resistance in several leukemia-cells and other cancer cell lines of different origin.
To delineate the effects of Salinomycin on CC, we established an in vitro cell culture model using three different human CC cell lines. After treatment apoptosis as well as migration and proliferation behavior was assessed and additional cell cycle analyses were performed by flowcytometry.
By demonstrating Annexin V and TUNEL positivity of human CC cells, we provide evidence that Salinomycin reveals the capacity to break apoptosis-resistance in CC cells. Furthermore, we are able to demonstrate that the non-apoptotic cell fraction is characterized by sustainable impaired migration and proliferation. Cell cycle analyses revealed G2-phase accumulation of human CC cells after treatment with Salinomycin. Even though apoptosis is induced in two of three cell lines of CC cells, one cell line remained unaffected in regard of apoptosis but revealed as the other CC cells decreased proliferation and migration.
In this study, we are able to demonstrate that Salinomycin is an effective agent against previously resistant CC cells and might be a potential candidate for the treatment of CC in the future.
KeywordsSalinomycin Cholangiocarcinoma Apoptosis Tumor cell migration Cell cycle
Cholangiocarcinoma (CC) is an adenocarcinoma arising from the biliary epithelial cells and can affect both the intra- and extrahepatic biliary tree . Beside hepatocellular carcinoma (HCC) it is the most common liver cancer with increasing incidence over the past years [2–4]. While in Asian countries the high incidence of CC is associated with liver flukes also in Northern America and Europe intrahepatic CC occurs in increasing number of unknown reason . Patient´s survival is dramatically restricted due to limited treatment options and advanced stage of disease at presentation . Thus treatment of CC is currently one of the biggest challenges in modern oncology. The only curative treatment options for this kind of cancer are radical surgical resection or as performed in some centers for a selected subset of patients liver transplantation [5, 6]. Chemotherapy is less effective; however, a new protocol combining Gemcitabine and Cisplatin might be a promising therapeutical strategy for patients with advanced CC . Limited data is available on the exact pathomechanisms leading to the development of CC. Chronic inflammatory conditions, such as primary sclerosing cholangitis, congenital biliary disorders, infection with liver flukes or toxic agents are supposed to be related to the malignant transformation of the biliary epithelial cells .
Salinomycin is a polyether antibiotic, originally isolated from Streptomyces albus. It acts as a potassium ionophore and thereby interferes with transmembrane potassium potential, leading to mitochondrial and cellular potassium efflux [10, 11]. Salinomycin is widely-used as an anticoccidial in poultry  and as a dietary supplement in ruminants` and pigs` breed [13, 14]. Recently, the potential of Salinomycin as an anti-cancer agent has been elucidated . First, the effects of Salinomycin were described in the treatment of cancer stem cells in vitro and in vivo. Later, the efficacy of Salinomycin against tumor cells has been demonstrated in several cancer cell lines from different origin, including solid and non-solid malignancies [17–20]. Nevertheless, the precise mode of action of Salinomycin as an anti-cancer agent remains unclear.
So far, the impact of Salinomycin treatment on human CC cells has not been investigated. Thus, the aim of the present study was to investigate whether the anti-cancer effect of Salinomycin is also sufficient for the treatment of CC. We identified that Salinomycin induces apoptosis in human CC cells in vitro. In addition, we demonstrate that Salinomycin impairs tumor cell migration, reduces tumor cell proliferation and leads to cell cycle accumulation. Our data provide that treatment of human CC cells with Salinomycin has a promising anti-cancer effect.
Cell lines and culture
For proof of principle of the properties of Salinomycin the reactivity of three well characterized human CC cell lines, Mz-ChA-1 , TFK-1 and EGI-1 [21–23] was tested. Cells were cultured at 37°C and 5% CO2 in culture medium (RPMI 1640 + Glutamax, supplemented with 10% fetal bovine serum, 10 mM HEPES-Buffer, 1% MEM non-essential Amino acids, penicillin (50 U/ml), and streptomycin (50 mg/l)) (Invitrogen, Darmstadt, Germany). Medium was changed every 48 hours. Mz-ChA-1 cells were a kind gift from Dr. A Knuth (Universitiy Hospital of Zurich, Zurich, Switzerland). TFK-1 and EGI-1 cells were provided by S. Zender (Hannover Medical School, Hannover, Germany). Jurkat cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 mg/l), at 37°C and 5% CO2. Cells were maintained by passages every 72 hours.
Salinomycin was purchased from Sigma-Aldrich (Munich, Germany) and dissolved in DMSO. Gemcitabine was purchased from TEVA (Radebeul, Germany) and dissolved in phosphate buffered saline (PBS). Stock solutions were stored at −20°C.
1 × 103 human CC cells were cultured in medium alone or in the presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin in 96-well flat bottom plates. The cultures were expanded for different time periods: either 24 or 48 hours under treatment of reagents respectively or first exposed to Gemcitabine and Salinomycin for 48 hours followed by additional 48 hours in medium alone. For the last 16 hours of culture cells were pulsed with 1 μCi 3H-Thymidine and incorporation was assessed using a β-counter (LKB Wallac, Turku, Finland).
Cell cycle analysis
Cell cycle analysis was performed using the CellTest Plus Reagent Kit (Becton Dickinson Imunocytometry Systems, San Jose, California, USA). 1 × 105 human CC cells were seeded in 12-well plates for 24 hours without reagents to allow attachment. Cells were then incubated in the presence or absence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 24 hours, trypsinized and stained according to the manufacturer´s instructions. Analysis was performed using a FACSCalibur (BD Bioscience, Heidelberg, Germany) and the ModFit LD software (Verity House Software, Topsham, Maine, USA).
Tumor cell migration was analyzed using a transwell chamber (Corning Coster, Corning, NY, USA) provided with an 8 μm pore polycarbonate membrane. Human CC cells were placed at 5 × 105 cells/well in culture medium containing 10% fetal calf serum in the upper compartment of the chamber. The lower compartment was filled with culture medium containing 30% fetal calf serum acting as a chemo-attractant . Cells were cultured in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 48 hours. The membrane was then removed, fixed with ethanol and stained with hematoxylin. The membranes were analyzed under a light microscope counting the number of migrated cells to the lower surface of the membrane in five randomly selected fields as described before .
Annexin V analysis
Human CC cells were plated in 6-well plates at 1 × 106 cells/well in culture medium and grown until confluence. Cells were further incubated in the presence or absence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 24 hours. Cells were trypsinized and washed two times with PBS. Induction of apoptosis was assessed using Annexin V apoptosis detection kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer`s instructions. Analysis was performed with a FACSCalibur (BD Biosciences).
Terminal desoxynucleotidyl transferase (dUTP) nick end labeling (TUNEL) assay
3 × 104 human CC cells were cultured in 8-well glass chamber slides (Nunc, Rochester, NY, USA) until confluence in medium alone and further on for 24 hours in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin. Cells were fixed with 4% paraformaldehyde for 25 min at 4°, washed with PBS and permeabilized by methanol/acetone solution for 10 min. Cells were equilibrated with equilibration buffer (Promega, Madison, Wisconsin, USA) for 5–10 min at room temperature. After washing with PBS cells were incubated with rTDT incubation buffer for 60 min at 37°. Reaction was stopped with 20x concentrated SSC buffer and washed with PBS. Nuclei staining was performed by adding DAPI 1:2500 (Sigma, St. Louis, Missouri, USA) in PBS during the final washing procedure. Cells were mounted in VECTASHIELD and analyzed within 24 hours. TUNEL assay was performed using a commercial kit (Promega, Madison, Wisconsin, USA).
3 × 104 adherent human CC cells were cultured in chamber slides in medium until confluence. Cells were further cultured in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 24 hours. Cells were fixed with 4% paraformaldehyde for 25 min at 4°, washed with PBS and air-dried for 1 hour. As positive control for Caspase-dependent induction of apoptosis human Jurkat cells were exposed to human TRAIL-expressing transgenic fibroblasts for 12 hours. Jurkat cells were subsequently washed from adherent fibroblasts and air-dried on slides after cytospin centrifugation (Shandon Cytospin GMI, Ramsay, Minnesota, USA). All samples were fixed by acetone/methanol solution and afterwards air-dried for one hour. Analysis of activated caspases was performed using a monoclonal antibody against cleaved caspase-3 (New England Biolabs, Ipswich, Massachusetts, USA) diluted 1:200 in PBS. Staining was visualized using Cy3-labeled secondary donkey anti-rabbit antibody (Biolegend, San Diego, California, USA) diluted 1:500 in PBS. Nuclei staining was performed by adding DAPI 1:2500 in PBS during the final washing procedure. Cells were analyzed using the AxiolmagerM1 microscope (Zeiss, Jena, Germany) and the AxioVision 4.6 software (Zeiss).
Results were expressed as mean ± SD. All experiments were performed at least in three individual experiments. Results were analyzed for statistical significance using two-way ANOVA test or student´s t-test.
Exposure of Salinomycin to human CC cells provokes morphological changes
Salinomycin induces apoptosis in human CC cells
Regarding that apoptosis is typically characterized by an activation of caspases we investigated if induction of apoptosis by Salinomycin in human CC cells is also accompanied by activated caspases. Therefore, we used a monoclonal antibody against caspase-3. Interestingly, activated caspase-3 was not found in Salinomycin-induced apoptosis in human CC cells (Figure 3C). Neither incubation of Mz-ChA-1 cells with 5 μM nor with 10 μM Salinomycin resulted in an activation of caspase-3. Also exposure of TFK-1 and EGI-1 cells to equivalent amounts of Salinomycin did not result in activated caspase-3. A non-effectiveness of the staining procedure was excluded by evidence of activated caspase-3 in apoptotic Jurkat cells after exposure to human TRAIL expressing transgenic fibroblasts (Figure 3C).
Impaired tumor cell migration after treatment with Salinomycin
Enduring reduced proliferation of human CC cells after treatment with Salinomycin
Salinomycin influences the cell cycle of human CC cells
In this study we demonstrate that resistance to apoptosis of CC cells can be overcome by treatment with Salinomycin. We show that two of three cell lines respond to Salinomycin-treatment with a significant degree of apoptosis independent of Caspase-3 activity. In addition, Salinomycin inhibits cell proliferation and cell migration. Of note, this accounts for all three tested cell lines.
Patient´s survival suffering from CC is poor and even CC calls for up to 15% of all primary liver malignancies, the molecular pathogenesis is unclear to the greatest possible extent [2–4, 26]. Consequently, characterization of the molecular pathogenesis and development of innovative therapeutic strategies are imperatively required particularly since current approaches such as administration of Gemcitabine combined with Cisplatin are rather part of a palliative concept than a curative treatment strategy . This is most likely due to apoptosis resistance of CC cells and subsequently weak efficacy of common chemotherapeutical regimes. The induction of apoptosis in human CC cells is barely observed [25, 27] or only detectable after co-treatment of the cells with additional drugs or inhibiting RNAs [28–30]. Accordingly, the understanding and the therapy of CC are characterized by nescience and ineffectiveness.
This is highlighted by the fact that even with Salinomycin which revealed capacity to provoke apoptosis in two of three tested human CC cell lines, EGI-1 remained to be unaffected in terms of being predispositioned to apoptosis. Exposure of Salinomycin to Mz-ChA-1 and TFK-1 cells, which were both originally isolated from an extrahepatic bile duct carcinoma [21, 22], resulted in a high percentage of apoptotic tumor cells, while EGI-1 cells seem to be less susceptible for treatment with Salinomycin even after treatment with high concentrations. It has been reported that Salinomycin selectively affects malignant cells whereas non-malignant cells do not undergo apoptosis after treatment with Salinomycin [20, 31, 32]. Given that EGI-1 cells are originally isolated from a poorly differentiated human bile duct adenocarcinoma  and therewith undoubted are malignant, it remains unclear why these cells are nearly apoptosis-resistant to treatment with Salinomycin. These observations demand further investigations to elucidate potential escape mechanisms of tumor cells which might be important for a possible clinical application of Salinomycin in the future, indeed. Moreover, apoptosis-escape mechanisms of EGI-1 cells might explain in part the strong resistance of CC cells to chemotherapeutics in general.
However, the exact mechanisms by which Salinomycin induces apoptosis are still incomplete understood . Salinomycin-induced apoptosis in human cancer cells is mediated by an uncommon pathway and independent of typical mechanism like activated caspases, death receptors like the CD95/DC95 ligand system or tumor suppressor protein p53 [15, 19]. Demonstrating that Salinomycin-induced apoptosis in human CC cells is independent of caspase-3 activation confirms that apoptosis is mediated through an uncommon pathway. Given that caspase-3 is activated both in the extrinsic and intrinsic pathway of apoptosis and plays a predominant role [33, 34], it is astonishing that none of the common pathways seems to be involved. Although activated caspase-3 can be found in apoptotic CC cells after treatment with Lobaplatin in vitro another not yet discovered apoptotic pathway appears to be responsible for the effects of Salinomycin. Recently, it was reported that the Wingless type (Wnt)/β-catenin signaling pathway could be involved . In chronic lymphocytic leukemia cells, Salinomycin inhibits the Wnt signaling cascade by blocking the phosphorylation of the Wnt co-receptor lipoprotein receptor related protein 6 (LRP6) causing impaired cell survival. These data are of great interest because in several tumor entities, LRP6 is over-expressed . Even if not completely understood, Wnt signaling might also play an important role in the carcinogenesis of CC  and recently, the effectiveness of several Wnt pathway inhibitors on human CC cells has been demonstrated . Additionally, it was reported that Salinomycin induces apoptosis in prostate cancer cells via accumulation of reactive oxygen species and mitochondrial membrane depolarization . Furthermore, Salinomycin inhibits prostate cancer growth via reduction of the expression of key oncogenes and induction of oxidative stress in cultured prostate cancer cells . Taken together, several mechanisms are supposed to be responsible for the effects of Salinomycin to human cancer cells, which have to be investigated in greater detail in the near future.
Furthermore, we demonstrate that the proportion of non-apoptotic tumor cells following Salinomycin-treatment is sustainable affected, characterized by impaired tumor cell migration, reduced proliferation and cell cycle accumulation. These observations are noteworthy due to well-known counterproductive reactions of tumor cells that escaped apoptosis, including hyperproliferation. To further characterize the effects induced by Salinomycin particularly on the continuous apoptosis-resisting EGI-1 cells, we investigated the ability of human CC cells to migrate after drug exposure. Tumor cell migration and therewith the ability to form metastases is a hallmark of tumors. While Ketola et al. have described impaired migration of prostate cancer cells after treatment with Salinomycin in a wound-healing assay ; this is the first report that migration through a membrane is effectively inhibited. These observations disclose an additional anti-cancer effect of Salinomycin in which all three cell lines are included.
Furthermore, the assessment of CC cell proliferation with or without Salinomycin treatment revealed a significant reduction of cell division in the presence of the agent. Again, all three cell lines, even EGI-1 cells, have shown this effect. We further demonstrate that Salinomycin- treatment of human CC cells induced an enduring reduced proliferation even after the abolition of treatment. This long-lasting effect demonstrates that the proportion of human CC cells that have escaped apoptosis after Salinomycin-treatment are affected permanently. These observations might be of particular importance for the potential clinical use of Salinomycin in the future as a prolonged effect of Salinomycin in patients with CC could also be expected.
In addition, we were able to correlate the anti-proliferative effects of Salinomycin with the results of the cell cycle analyses. The impact of Salinomycin on human CC cells is reflected by cell cycle accumulation in the G2-phase. This finding is noticeable because others have demonstrated that treatment with Salinomycin in equal concentrations is associated with accumulation in the pre-G1-phase, indicating increased apoptosis  Furthermore, in pre-treated human breast cancer with anti-mitotic drugs, Salinomycin abolishes G2-arrest and aneuploid cell formation [17, 40]. In contrast, radiation-treated breast cancer cells accumulate in the G2-phase after treatment with Salinomycin . Interestingly, Salinomycin-induced apoptosis in human leukemia cells is not accompanied by cell cycle arrest at all . Thus, in respect to our data, it seems that the effects of Salinomycin on cell cycle are not consistent between human tumor cells of different origin. This again demonstrates the existing nebulosity concerning the biochemical mechanisms affected by Salinomycin.
Demonstrating the capability of Salinomycin to induce apoptosis and to interfere with tumor cell motility and proliferation in human CC cells, a potential and promising therapeutical approach for the treatment of CC might be discovered. Particularly, cancer entities with such calamitous prognosis like CC are tremendously dependent on innovative and sufficient therapy concepts. Thereby different human CC cell lines should be analyzed in regard to their susceptibility to Salinomycin-treatment. Furthermore, animal models have to be developed to investigate the impact of Salinomycin in vivo. To what extend Salinomycin will achieve to be a candidate for anti-cancer therapies in the future remains to be seen. Given that lethal intoxication in humans and animals are described [42–44], potential clinical studies must be planned very thoughtful. Thus, finding the dosage of Salinomycin will be crucial for its application in prospective therapeutical regimes.
Salinomycin exhibits anti-tumor effects on human CC in vitro. Therefore, it should be considered as an innovative approach for the treatment of CC in the future and is worth to design further studies to proof practicability.
Desoxynucleotidy transferase nick end labeling
Lipoprotein related protein.
The authors are thankful to Matthias Hardtke-Wolenski for assistance with the fluorescence microscope, to Jutta Lamle for help to interpret cell cycle analyses and to Florian Vondran for his critical review of the manuscript. This work was supported in part by Hannelore-Munke Fellowship and Gottfried-Arndt-Stiftung to J.K.
- Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology. 2005, 128 (6): 1655-1667. 10.1053/j.gastro.2005.03.040.View ArticlePubMedGoogle Scholar
- Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004, 24 (2): 115-125. 10.1055/s-2004-828889.View ArticlePubMedGoogle Scholar
- Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006, 98 (12): 873-875. 10.1093/jnci/djj234.View ArticlePubMedGoogle Scholar
- Blechacz B, Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008, 48 (1): 308-321. 10.1002/hep.22310.View ArticlePubMedPubMed CentralGoogle Scholar
- Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001, 234 (4): 507-517. 10.1097/00000658-200110000-00010. discussion 517–509View ArticlePubMedPubMed CentralGoogle Scholar
- Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ: Transplantation for cholangiocarcinoma: when and for whom?. Surg Oncol Clin N Am. 2009, 18 (2): 325-337. 10.1016/j.soc.2008.12.008. ixView ArticlePubMedGoogle Scholar
- Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362 (14): 1273-1281. 10.1056/NEJMoa0908721.View ArticlePubMedGoogle Scholar
- Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M, Glaser SS: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008, 14 (19): 2986-2989. 10.3748/wjg.14.2986.View ArticlePubMedPubMed CentralGoogle Scholar
- Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C: Salinomycin, a new polyether antibiotic. J Antibiot (Tokyo). 1974, 27 (11): 814-821. 10.7164/antibiotics.27.814.View ArticleGoogle Scholar
- Mitani M, Yamanishi T, Miyazaki Y: Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun. 1975, 66 (4): 1231-1236. 10.1016/0006-291X(75)90490-8.View ArticlePubMedGoogle Scholar
- Mitani M, Yamanishi T, Miyazaki Y, Otake N: Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother. 1976, 9 (4): 655-660. 10.1128/AAC.9.4.655.View ArticlePubMedPubMed CentralGoogle Scholar
- Daugschies A, Gasslein U, Rommel M: Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials. Vet Parasitol. 1998, 76 (3): 163-171. 10.1016/S0304-4017(97)00203-3.View ArticlePubMedGoogle Scholar
- Callaway TR, Edrington TS, Rychlik JL, Genovese KJ, Poole TL, Jung YS, Bischoff KM, Anderson RC, Nisbet DJ: Ionophores: their use as ruminant growth promotants and impact on food safety. Curr Issues Intest Microbiol. 2003, 4 (2): 43-51.PubMedGoogle Scholar
- Lindemann MD, Kornegay ET, Stahly TS, Cromwell GL, Easter RA, Kerr BJ, Lucas DM: The efficacy of salinomycin as a growth promotant for swine from 9 to 97 kg. J Anim Sci. 1985, 61 (4): 782-788.PubMedGoogle Scholar
- Naujokat C, Fuchs D, Opelz G: Salinomycin in cancer: A new mission for an old agent. Mol Med Report. 2010, 3 (4): 555-559.View ArticleGoogle Scholar
- Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009, 138 (4): 645-659. 10.1016/j.cell.2009.06.034.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S: Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011, 162 (3): 773-784. 10.1111/j.1476-5381.2010.01089.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH: Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011, 18 (6): 1797-1804. 10.1245/s10434-011-1561-2.View ArticlePubMedGoogle Scholar
- Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010, 394 (4): 1098-1104. 10.1016/j.bbrc.2010.03.138.View ArticlePubMedGoogle Scholar
- Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009, 390 (3): 743-749. 10.1016/j.bbrc.2009.10.042.View ArticlePubMedGoogle Scholar
- Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995, 177 (1): 61-71. 10.1620/tjem.177.61.View ArticlePubMedGoogle Scholar
- Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Buschenfelde KH Mz: Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol. 1985, 1 (6): 579-596. 10.1016/S0168-8278(85)80002-7.View ArticlePubMedGoogle Scholar
- International Conference on Tumor Necrosis Factor and Related Cytotoxins: September 14–18, 1987, Heidelberg, Federal Republic of Germany. Abstracts. Immunobiology. 1987, 175 (1–2): 1-143.Google Scholar
- Ishimura N, Isomoto H, Bronk SF, Gores GJ: Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2006, 290 (1): G129-136.View ArticlePubMedGoogle Scholar
- Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ: A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010, 52 (2): 550-561. 10.1002/hep.23729.View ArticlePubMedPubMed CentralGoogle Scholar
- Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 2005, 366 (9493): 1303-1314. 10.1016/S0140-6736(05)67530-7.View ArticlePubMedGoogle Scholar
- Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol. 2007, 13 (33): 4458-4466.View ArticlePubMedPubMed CentralGoogle Scholar
- Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ: Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012, 32 (3): 400-409.PubMedGoogle Scholar
- Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T: Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis. Cancer Lett. 2010, 296 (1): 27-34. 10.1016/j.canlet.2010.03.011.View ArticlePubMedGoogle Scholar
- Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR, Kim DG: Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Exp Mol Med. 2010, 42 (11): 787-797. 10.3858/emm.2010.42.11.082.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011, 108 (32): 13253-13257. 10.1073/pnas.1110431108.View ArticlePubMedPubMed CentralGoogle Scholar
- Ketola K, Hilvo M, Hyotylainen T, Vuoristo A, Ruskeepaa AL, Oresic M, Kallioniemi O, Iljin K: Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012, 106 (1): 99-106. 10.1038/bjc.2011.530.View ArticlePubMedPubMed CentralGoogle Scholar
- Salvesen GS: Caspases and apoptosis. Essays Biochem. 2002, 38: 9-19.View ArticlePubMedGoogle Scholar
- Salvesen GS: Caspases: opening the boxes and interpreting the arrows. Cell Death Differ. 2002, 9 (1): 3-5. 10.1038/sj.cdd.4400963.View ArticlePubMedGoogle Scholar
- Wang Z, Tang X, Zhang Y, Qi R, Li Z, Zhang K, Liu Z, Yang X: Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE. Biomed Pharmacother. 2012, 66 (3): 161-166. 10.1016/j.biopha.2011.09.008.View ArticlePubMedGoogle Scholar
- Liu CC, Prior J, Piwnica-Worms D, Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A. 2010, 107 (11): 5136-5141. 10.1073/pnas.0911220107.View ArticlePubMedPubMed CentralGoogle Scholar
- Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, et al: Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005, 27 (4): 973-980.PubMedGoogle Scholar
- Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C, Di Fazio P, Ocker M, Berr F, Kiesslich T: Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012, 8 (1): 15-29.View ArticlePubMedGoogle Scholar
- Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, Song CS, Chatterjee B, Ahn SC: Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011, 413 (1): 80-86. 10.1016/j.bbrc.2011.08.054.View ArticlePubMedGoogle Scholar
- Kim JH, Yoo HI, Kang HS, Ro J, Yoon S: Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun. 2012, 418 (1): 98-103. 10.1016/j.bbrc.2011.12.141.View ArticlePubMedGoogle Scholar
- Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 2012, 30 (4): 1311-1318. 10.1007/s10637-011-9685-6.View ArticlePubMedGoogle Scholar
- Story P, Doube A: A case of human poisoning by salinomycin, an agricultural antibiotic. N Z Med J. 2004, 117 (1190): U799-PubMedGoogle Scholar
- Plumlee KH, Johnson B, Galey FD: Acute salinomycin toxicosis of pigs. J Vet Diagn Invest. 1995, 7 (3): 419-420. 10.1177/104063879500700327.View ArticlePubMedGoogle Scholar
- Kosal ME, Anderson DE: An unaddressed issue of agricultural terrorism: a case study on feed security. J Anim Sci. 2004, 82 (11): 3394-3400.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/466/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.